BioSpace News Archive

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) today announced that its subsidiary, Oravax Medical Inc., reported positive preliminary data from its Phase 1 trial of an oral Covid-19 vaccine candidate.

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announces today that its Board of Directors has empowered its Business Review Committee to evaluate opportunities to realize optimal shareholder value.

The United Steelworkers union (USW) is encouraging Ontario miners diagnosed with amyotrophic lateral sclerosis (ALS) or motor neuron diseases (MNDs) to participate in crucial research to confirm whether the diseases are occupational illnesses that qualify for compensation.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”) is pleased to announce the dosing of the first patient in the therapeutic phase of its Phase I/II theranostic trial evaluating 64Cu/67Cu SAR-bisPSMA theranostic products in patients with metastatic, castrate-resistant prostate cancer (mCRPC).

WallachBeth Capital LLC announced today that Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion, announced the pricing of an underwritten public offering of 3,777,778 units at an offering price of $1.35 per unit.

LAVATherapeuticsN.V.(Nasdaq:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the Company will present data demonstrating on-mechanism pharmacodynamics for LAVA-051 in the clinic during the Society for Immunotherapy of Cancer’s 37th Annual Meeting.

Candesant Biomedical (“Candesant”) today announced the “SweatTech Initiative” to raise awareness of the significant impact of excessive sweating, educate on how treatments have evolved over the decades, and demonstrate the ongoing need for more modern treatments.

Galderma announced today that it will be showcasing its latest scientific updates at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting taking place October 6-10, 2022, in Aurora, Colorado.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the presentation of new biomarker analyses supporting the therapeutic benefit of NurOwn® in amyotrophic lateral sclerosis (ALS) at the ongoing 5th Annual ALS ONE Research Symposium.

Today, the U.S. Food and Drug Administration approved Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age.